MCID: LNG039
MIFTS: 60

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Lung 12 28 69
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 51

Classifications:



External Ids:

Disease Ontology 12 DOID:3907
NCIt 46 C3493
SNOMED-CT 64 254634000
UMLS 69 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and large cell carcinoma. An important gene associated with Lung Squamous Cell Carcinoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Carboplatin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Squamous-cell carcinoma (SCC) of the lung is a type of non-small-cell lung carcinoma and is more common... more...

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.3 BRAF CYP1A1 EGFR FGFR2 HRAS KRT19
2 large cell carcinoma 30.9 EGFR FGFR1 PTHLH
3 adenosquamous carcinoma 30.7 EGFR KRAS PTHLH TP53
4 adenocarcinoma 30.6 BRAF EGFR FGFR2 HRAS KRAS NAPSA
5 intrahepatic cholangiocarcinoma 30.3 EGFR FGFR2 KRAS KRT19 TP53
6 lung cancer 28.6 ALK BRAF CYP1A1 EGFR FGFR1 FGFR2
7 lung occult squamous cell carcinoma 11.2
8 lung mixed small cell and squamous cell carcinoma 11.2
9 brain ependymoma 10.7 EGFR TP53
10 parameningeal embryonal rhabdomyosarcoma 10.7 ALK TP53
11 plagiocephaly 10.7 FGFR1 FGFR2
12 pulmonary blastoma 10.6 EGFR KRAS TP53
13 breast metaplastic carcinoma 10.6 EGFR PTHLH TP53
14 pleomorphic carcinoma 10.6 ALK EGFR TP53
15 nevus of ota 10.6 BRAF TP53
16 adult hepatocellular carcinoma 10.6 PIK3CA TP53
17 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.6 KRAS PIK3CA TP53
18 hyperplastic polyposis syndrome 10.6 BRAF KRAS TP53
19 oral cavity cancer 10.6 CYP1A1 EGFR SOX2
20 estrogen-receptor positive breast cancer 10.6 EGFR FGFR2 PIK3CA TP53
21 mature teratoma 10.6 BRAF KRAS TP53
22 pinguecula 10.6 CYP1A1 KRT19 TP53
23 lung papillary adenocarcinoma 10.6 ALK KEAP1 NFE2L2 TP53
24 endometrial adenocarcinoma 10.6 EGFR KRAS TP53
25 small intestinal adenocarcinoma 10.6 BRAF EGFR KRAS
26 mucinous adenocarcinoma 10.6 ALK EGFR KRAS TP53
27 brain cancer 10.5 ALK EGFR SOX2 TP53
28 giant cell glioblastoma 10.5 BRAF EGFR FGFR1 TP53
29 cerebellar astrocytoma 10.5 BRAF TP53
30 breast carcinoma in situ 10.5 FGFR1 KRT19 TP53
31 oral cancer 10.5 CYP1A1 EGFR KRT19 TP53
32 astrocytoma 10.5 EGFR FGFR1 KRAS TP53
33 tumor suppressor gene on chromosome 11 10.5 BRAF EGFR KRAS PIK3CA
34 malignant spiradenoma 10.5 PIK3CA TP53
35 gliosarcoma 10.5 EGFR FGFR1 TP53
36 ovarian clear cell carcinoma 10.4 KRAS NAPSA PIK3CA PTHLH TP53
37 sigmoid neoplasm 10.4 HRAS KRAS
38 paronychia 10.4 EGFR HRAS KRAS
39 ethmoid sinus cancer 10.4 EGFR HRAS PIK3CA
40 ethmoid sinus adenocarcinoma 10.4 EGFR HRAS PIK3CA
41 nasal cavity adenocarcinoma 10.4 HRAS KRAS TP53
42 apocrine adenoma 10.3 HRAS KRAS PIK3CA
43 penile cancer 10.3 EGFR HRAS TP53
44 ovary adenocarcinoma 10.3 HRAS KRAS TP53
45 mixed cell type cancer 10.3 HRAS KRAS TP53
46 aggressive digital papillary adenocarcinoma 10.3 HRAS KRAS PIK3CA
47 biliary tract neoplasm 10.3 HRAS KRAS TP53
48 spitz nevus 10.3 BRAF HRAS TP53
49 nevus, epidermal 10.3 HRAS KRAS PIK3CA
50 adenosquamous pancreas carcinoma 10.3 HRAS KRAS PTHLH

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

25 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.61 HRAS BRAF EGFR KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.61 KRAS
3 Decreased viability GR00107-A-1 10.61 PRKCI
4 Decreased viability GR00221-A-1 10.61 HRAS EGFR KRAS FGFR1 ALK SOX2
5 Decreased viability GR00221-A-2 10.61 HRAS KRAS FGFR1 PIK3CA PRKCI
6 Decreased viability GR00221-A-3 10.61 HRAS PRKCI
7 Decreased viability GR00221-A-4 10.61 BRAF EGFR ALK SOX2 PIK3CA PRKCI
8 Decreased viability GR00301-A 10.61 BRAF KRAS
9 Decreased viability GR00381-A-1 10.61 KRAS BRAF
10 Decreased cell migration GR00055-A-1 9.8 EGFR KRAS ALK BRAF HRAS PRKCI
11 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.55 BRAF FGFR1 FGFR2 ALK PRKCI
12 Increased cell migration GR00055-A-3 9.02 HRAS BRAF EGFR PIK3CA KRAS

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

43 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.48 BRAF EGFR ALK FGFR2 CYP1A1 FGFR1
2 cardiovascular system MP:0005385 10.43 FGFR1 EGFR BRAF FGFR2 CYP1A1 KRAS
3 endocrine/exocrine gland MP:0005379 10.43 BRAF EGFR ALK FGFR2 CYP1A1 FGFR1
4 homeostasis/metabolism MP:0005376 10.43 CYP1A1 FGFR2 FGFR1 BRAF EGFR ALK
5 mortality/aging MP:0010768 10.41 FGFR2 CYP1A1 FGFR1 EGFR BRAF ALK
6 behavior/neurological MP:0005386 10.4 ALK FGFR1 BRAF KRAS HRAS FGFR2
7 cellular MP:0005384 10.39 FGFR1 EGFR BRAF KRAS FGFR2 NFE2L2
8 digestive/alimentary MP:0005381 10.38 BRAF EGFR FGFR2 FGFR1 KEAP1 KRAS
9 integument MP:0010771 10.38 BRAF EGFR ALK FGFR2 FGFR1 KEAP1
10 embryo MP:0005380 10.33 FGFR2 FGFR1 BRAF EGFR KRAS NFE2L2
11 immune system MP:0005387 10.33 CYP1A1 FGFR1 EGFR BRAF KRAS FGFR2
12 craniofacial MP:0005382 10.3 FGFR1 BRAF EGFR FGFR2 KRAS HRAS
13 nervous system MP:0003631 10.3 FGFR2 FGFR1 EGFR BRAF ALK KRAS
14 adipose tissue MP:0005375 10.23 BRAF EGFR FGFR2 NFE2L2 PIK3CA PTHLH
15 neoplasm MP:0002006 10.22 BRAF EGFR ALK FGFR2 KRT19 KRAS
16 muscle MP:0005369 10.15 FGFR1 BRAF EGFR FGFR2 KRAS PIK3CA
17 normal MP:0002873 10.14 CYP1A1 FGFR2 FGFR1 BRAF EGFR KRAS
18 liver/biliary system MP:0005370 10.13 CYP1A1 EGFR BRAF KRAS FGFR2 NFE2L2
19 no phenotypic analysis MP:0003012 10.13 CYP1A1 FGFR2 FGFR1 EGFR KRAS HRAS
20 hearing/vestibular/ear MP:0005377 10.11 FGFR1 EGFR BRAF KRAS FGFR2 SOX2
21 renal/urinary system MP:0005367 10.02 FGFR2 FGFR1 EGFR BRAF KRAS HRAS
22 reproductive system MP:0005389 10 FGFR2 FGFR1 BRAF EGFR ALK KRAS
23 pigmentation MP:0001186 9.97 BRAF EGFR ALK FGFR2 KRAS PRKCI
24 respiratory system MP:0005388 9.9 BRAF EGFR ALK FGFR2 KEAP1 KRAS
25 skeleton MP:0005390 9.77 FGFR1 BRAF EGFR ALK FGFR2 KRAS
26 vision/eye MP:0005391 9.36 FGFR1 EGFR BRAF ALK FGFR2 KRAS

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
4
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
5
Nedaplatin Approved, Investigational Phase 4,Phase 3 95734-82-0
6
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
10
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
11 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
12
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
13 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
17 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
20 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
22 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
25 tyrosine Nutraceutical Phase 4,Phase 2,Phase 1
26 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
27
Cyclophosphamide Approved, Investigational Phase 3,Phase 1 50-18-0, 6055-19-2 2907
28
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
29
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
30
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
31
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
32
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
33
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
34
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
35
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
36
nivolumab Approved Phase 3,Phase 2 946414-94-4
37
Palbociclib Approved, Investigational Phase 2, Phase 3, Phase 1 571190-30-2 5330286 11431660 5005498
38
ponatinib Approved, Investigational Phase 2, Phase 3 943319-70-8 24826799
39
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
40
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
41 Talazoparib Investigational Phase 2, Phase 3 1207456-01-6
42
Tremelimumab Investigational Phase 2, Phase 3 745013-59-6
43 Alkylating Agents Phase 3,Phase 2,Phase 1
44 Antirheumatic Agents Phase 3,Phase 2,Phase 1
45 Etoposide phosphate Phase 3,Phase 2,Phase 1
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
48 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
49 Endostatins Phase 3 71581480
50 Hematinics Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 215)

# Name Status NCT ID Phase Drugs
1 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
2 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
3 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
4 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
5 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
6 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
7 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
8 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
9 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed NCT01523587 Phase 3 afatinib;erlotinib
10 Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Completed NCT01652469 Phase 3 Erlotinib;Docetaxel
11 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
12 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
13 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
14 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
15 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
16 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
17 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
18 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
19 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
20 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
21 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
22 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
23 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
24 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
25 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
26 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
27 Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting NCT02785952 Phase 3
28 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3 Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Talazoparib;Taselisib
29 A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC Recruiting NCT03150875 Phase 3 Docetaxel
30 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
31 Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC Recruiting NCT02455843 Phase 3
32 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
33 Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Active, not recruiting NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
34 Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
35 Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
36 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
37 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
38 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
39 Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer Not yet recruiting NCT03262948 Phase 3 nab-paclitaxel;Paclitaxel;Carboplatin
40 Photodynamic Therapy for the Prevention of Lung Cancer Not yet recruiting NCT03346304 Phase 2, Phase 3
41 Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer Not yet recruiting NCT03351361 Phase 3 Nivolumab + Ipilimumab;Chemotherapy
42 Ponatinib for Squamous Cell Lung and Head and Neck Cancers Terminated NCT01761747 Phase 2, Phase 3 ponatinib
43 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
44 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
45 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
46 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
47 Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
48 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
49 Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy Unknown status NCT01660399 Phase 2 Boanmycin;Docetaxel
50 Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer Unknown status NCT01494415 Phase 2 Paclitaxel for Injection(Albumin Bound);carboplatin

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Genetic tests related to Lung Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of Lung 28

Anatomical Context for Lung Squamous Cell Carcinoma

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

38
Lung, T Cells, Brain, Testes, Lymph Node, Bone, Endothelial

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 313)
# Title Authors Year
1
Identification of a progression-associated long non-coding RNA signature for predicting the prognosis of lung squamous cell carcinoma. ( 29434705 )
2018
2
Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells. ( 29286099 )
2018
3
CDKN1A-interacting zinc finger protein 1 is a novel biomarker for lung squamous cell carcinoma. ( 29285191 )
2018
4
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR. ( 29394946 )
2018
5
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. ( 29384143 )
2018
6
Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. ( 29318765 )
2018
7
Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. ( 29305708 )
2018
8
Integrated genomic analyses of lung squamous cell carcinoma for identification of a possible competitive endogenous RNA network by means of TCGA datasets. ( 29340250 )
2018
9
The Positive Relationship Between I^H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. ( 29275316 )
2018
10
Correction: Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. ( 29437123 )
2018
11
The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. ( 28724602 )
2017
12
ALK and ROS1 double-rearranged lung squamous cell carcinoma responding to crizotinib treatment: a case report. ( 28911956 )
2017
13
Protein regulator of cytokinesis-1 expression: prognostic value in lung squamous cell carcinoma patients. ( 28840006 )
2017
14
A Case of IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. ( 29279511 )
2017
15
Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma. ( 28881601 )
2017
16
YAP suppresses lung squamous cell carcinoma progression via deregulation of the DNp63-GPX2 axis and ROS accumulation. ( 28916653 )
2017
17
Identification of long noncoding RNAs for the detection of early stage lung squamous cell carcinoma by microarray analysis. ( 28076325 )
2017
18
Ferrerol overcomes the invasiveness of lung squamous cell carcinoma cells by regulating the expression of inducers of epithelial mesenchymal transition. ( 28943152 )
2017
19
Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma. ( 28604655 )
2017
20
Oligometastatic Stomach Carcinoma From Lung Squamous Cell Carcinoma Detected by 18F-FDG PET/CT. ( 28719444 )
2017
21
A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma. ( 28835135 )
2017
22
High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma. ( 28933054 )
2017
23
Role of afatinib in the treatment of advanced lung squamous cell carcinoma. ( 29225480 )
2017
24
Functional analysis of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in patients with lung squamous cell carcinoma. ( 28693175 )
2017
25
Identification of Key Transcription Factors Associated with Lung Squamous Cell Carcinoma. ( 28081052 )
2017
26
Lung Squamous Cell Carcinoma with De Novo c-Met Amplification. ( 28879708 )
2017
27
Sex-Determining Region Y-box 2 Promotes Growth of Lung Squamous Cell Carcinoma and Directly Targets Cyclin D1. ( 28151013 )
2017
28
Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma. ( 27884700 )
2017
29
Gli1 expression in cancer stem-like cells predicts poor prognosis in patients with lung squamous cell carcinoma. ( 28286162 )
2017
30
A case report of tongue metastasis from lung squamous cell carcinoma and literature review: Erratum. ( 29382026 )
2017
31
Co-expression of podoplanin and fibroblast growth factor 1 predicts poor prognosis in patients with lung squamous cell carcinoma. ( 28656229 )
2017
32
Co-expression network analysis of long noncoding RNAs (IncRNAs) and cancer genes revealsSFTA1P and CASC2abnormalities in lung squamous cell carcinoma. ( 28118064 )
2017
33
[Overexpression of OLC1 in Lung Squamous Cell Carcinoma Tissues is Associated with Poor Prognosis of Patients]. ( 28532543 )
2017
34
Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma. ( 28800867 )
2017
35
Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth. ( 28794006 )
2017
36
Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. ( 28881841 )
2017
37
Diagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma: a study based on the Cancer Genome Atlas. ( 29204322 )
2017
38
Airway Basal Cell Heterogeneity and Lung Squamous Cell Carcinoma. ( 28821543 )
2017
39
Long non-coding RNA SNHG1 regulates zinc finger E-box binding homeobox 1 expression by interacting with TAp63 and promotes cell metastasis and invasion in Lung squamous cell carcinoma. ( 28415044 )
2017
40
Comprehensive investigation of clinicopathologic features, oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma. ( 29268512 )
2017
41
Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. ( 29279354 )
2017
42
Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma. ( 28214218 )
2017
43
Differential protein-coding gene and long noncoding RNA expression in smoking-related lung squamous cell carcinoma. ( 28949095 )
2017
44
Long noncoding RNA<i>SFTA1P</i>promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma. ( 29228625 )
2017
45
Risk factors of lymph node metastasis in lung squamous cell carcinoma of 3a88cm or less in diameter. ( 28723786 )
2017
46
ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. ( 28683775 )
2017
47
Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma. ( 29221266 )
2017
48
STXBP4 drives tumor growth and is associated with poor prognosis through PDGF Receptor signaling in lung squamous cell carcinoma. ( 28087642 )
2017
49
A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinoma. ( 28881596 )
2017
50
A three-microRNA signature for lung squamous cell carcinoma diagnosis in Chinese male patients. ( 29156844 )
2017

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 63)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
7 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
10 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
12 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
13 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
14 FGFR2 NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121918499 GRCh37 Chromosome 10, 123279562: 123279562
15 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
16 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
17 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
19 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
23 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
24 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
25 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
26 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
27 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
28 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
29 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
30 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh38 Chromosome 3, 179210192: 179210192
31 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
32 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
33 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
34 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
35 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
36 EGFR NM_005228.4(EGFR): c.2303G> T (p.Ser768Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913465 GRCh37 Chromosome 7, 55249005: 55249005
37 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
38 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
39 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
40 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
41 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
42 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh38 Chromosome 17, 7675190: 7675190
43 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
44 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
45 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
46 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
47 EGFR NM_005228.4(EGFR): c.2582T> A (p.Leu861Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913444 GRCh37 Chromosome 7, 55259524: 55259524
48 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
49 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
50 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 2856)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM96301 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522V 17
2 COSM6492724 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 17
3 COSM6492589 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 17
4 COSM4987559 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 17
5 COSM6490907 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 17
6 COSM6491476 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 17
7 COSM6491424 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 17
8 COSM6492792 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 17
9 COSM95568 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.551G>A p.R184H 17
10 COSM3717849 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 17
11 COSM6492197 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 17
12 COSM6492124 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 17
13 COSM96300 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36L 17
14 COSM95561 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 17
15 COSM6492895 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.597G>A p.T199T 17
16 COSM6492512 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.587G>A p.G196D 17
17 COSM6492817 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.99G>T p.V33V 17
18 COSM6492224 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.64C>A p.H22N 17
19 COSM6492511 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.138C>T p.A46A 17
20 COSM6492818 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.979A>T p.T327S 17
21 COSM6492896 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.244C>T p.H82Y 17
22 COSM6491849 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.430C>G p.P144A 17
23 COSM6491404 ZFHX4 lung,NS,carcinoma,squamous cell carcinoma c.2919G>T p.L973L 17
24 COSM6492881 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.8849G>T p.R2950L 17
25 COSM6491202 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.5661A>G p.K1887K 17
26 COSM6491691 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.6884A>T p.Q2295L 17
27 COSM6491571 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.3074G>C p.R1025T 17
28 COSM6492450 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.708G>T p.K236N 17
29 COSM6491664 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.515C>T p.T172I 17
30 COSM6491233 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.2418C>T p.F806F 17
31 COSM6492147 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.2805G>A p.M935I 17
32 COSM95691 ZCCHC2 lung,NS,carcinoma,squamous cell carcinoma c.3073G>T p.G1025* 17
33 COSM95554 ZAP70 lung,NS,carcinoma,squamous cell carcinoma c.188G>A p.R63H 17
34 COSM95552 YWHAG lung,NS,carcinoma,squamous cell carcinoma c.113C>T p.S38L 17
35 COSM96294 YWHAE lung,NS,carcinoma,squamous cell carcinoma c.660C>T p.I220I 17
36 COSM95549 YAP1 lung,NS,carcinoma,squamous cell carcinoma c.485A>G p.Q162R 17
37 COSM95539 WWP2 lung,NS,carcinoma,squamous cell carcinoma c.1892A>T p.Y631F 17
38 COSM6491996 WWC3 lung,NS,carcinoma,squamous cell carcinoma c.3223G>C p.A1075P 17
39 COSM6492685 WWC2 lung,NS,carcinoma,squamous cell carcinoma c.2117T>A p.L706H 17
40 COSM6491365 WWC1 lung,NS,carcinoma,squamous cell carcinoma c.1093G>T p.G365W 17
41 COSM95536 WT1 lung,NS,carcinoma,squamous cell carcinoma c.857A>G p.Y286C 17
42 COSM95535 WRN lung,NS,carcinoma,squamous cell carcinoma c.3934G>T p.V1312F 17
43 COSM95533 WNT9B lung,NS,carcinoma,squamous cell carcinoma c.109C>A p.P37T 17
44 COSM95530 WNT7B lung,NS,carcinoma,squamous cell carcinoma c.128G>T p.G43V 17
45 COSM95525 WNT2 lung,NS,carcinoma,squamous cell carcinoma c.805G>T p.V269L 17
46 COSM95524 WNT16 lung,NS,carcinoma,squamous cell carcinoma c.217G>T p.G73C 17
47 COSM96286 WNT10B lung,NS,carcinoma,squamous cell carcinoma c.702G>T p.V234V 17
48 COSM95522 WNT10B lung,NS,carcinoma,squamous cell carcinoma c.364T>A p.S122T 17
49 COSM21240 WNK3 lung,NS,carcinoma,squamous cell carcinoma c.2561C>G p.S854C 17
50 COSM96285 WNK1 lung,NS,carcinoma,squamous cell carcinoma c.2094C>T p.V698V 17

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss LOC645166 Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF16 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain C19orf63 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss IN Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss LOC654342 Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP73L Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 ALK BRAF CDH10 EGFR FGFR1 FGFR2
2
Show member pathways
13.81 ALK BRAF EGFR FGFR1 FGFR2 HRAS
3
Show member pathways
13.74 ALK BRAF EGFR FGFR1 FGFR2 HRAS
4
Show member pathways
13.62 ALK BRAF EGFR FGFR1 FGFR2 HRAS
5
Show member pathways
13.59 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
6
Show member pathways
13.54 EGFR FGFR1 FGFR2 HRAS KEAP1 KRAS
7
Show member pathways
13.5 ALK EGFR FGFR1 FGFR2 HRAS KRAS
8
Show member pathways
13.45 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
9
Show member pathways
13.4 ALK EGFR FGFR1 FGFR2 HRAS KRAS
10
Show member pathways
13.33 ALK BRAF CDH10 EGFR FGFR1 FGFR2
11
Show member pathways
13.15 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
12
Show member pathways
13.13 ALK EGFR FGFR1 FGFR2 HRAS KRAS
13
Show member pathways
13.07 ALK EGFR FGFR1 FGFR2 HRAS PRKCI
14
Show member pathways
13.06 ALK BRAF EGFR FGFR1 FGFR2 HRAS
15
Show member pathways
13.05 EGFR FGFR1 FGFR2 HRAS KRAS PIK3CA
16
Show member pathways
12.99 BRAF EGFR HRAS KRAS PIK3CA PRKCI
17
Show member pathways
12.94 BRAF EGFR HRAS KRAS PIK3CA
18
Show member pathways
12.89 BRAF HRAS KRAS PIK3CA PRKCI
19
Show member pathways
12.85 BRAF HRAS KRAS PIK3CA PRKCI
20 12.84 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
21
Show member pathways
12.81 EGFR FGFR1 FGFR2 HRAS KRAS PIK3CA
22
Show member pathways
12.79 BRAF HRAS KRAS PIK3CA TP53
23
Show member pathways
12.79 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
24
Show member pathways
12.76 BRAF EGFR HRAS KRAS PRKCI TP53
25
Show member pathways
12.75 BRAF EGFR HRAS KRAS PRKCI
26 12.71 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
27
Show member pathways
12.68 EGFR HRAS KRAS PIK3CA TP53
28
Show member pathways
12.67 BRAF EGFR HRAS KRAS PIK3CA TP53
29
Show member pathways
12.66 BRAF FGFR1 FGFR2 HRAS KRAS PIK3CA
30
Show member pathways
12.62 BRAF EGFR FGFR1 FGFR2 HRAS KEAP1
31 12.6 EGFR HRAS KRAS PIK3CA TP53
32
Show member pathways
12.57 BRAF EGFR HRAS KRAS PIK3CA TP53
33
Show member pathways
12.55 BRAF EGFR HRAS KRAS PIK3CA PRKCI
34
Show member pathways
12.54 FGFR1 FGFR2 HRAS KRAS PIK3CA PRKCI
35 12.49 HRAS KRAS PIK3CA TP53
36
Show member pathways
12.49 BRAF HRAS KRAS PIK3CA PRKCI
37
Show member pathways
12.47 EGFR HRAS KRAS PIK3CA
38 12.47 EGFR FGFR2 HRAS PRKCI
39
Show member pathways
12.47 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
40
Show member pathways
12.46 EGFR FGFR1 FGFR2 HRAS
41
Show member pathways
12.45 BRAF HRAS KRAS PIK3CA
42
Show member pathways
12.44 HRAS KRAS PRKCI TP53
43
Show member pathways
12.43 EGFR HRAS KRAS PRKCI
44 12.42 ALK BRAF EGFR FGFR1 FGFR2 HRAS
45
Show member pathways
12.39 HRAS KRAS PIK3CA PRKCI
46
Show member pathways
12.39 EGFR HRAS KRAS PIK3CA
47 12.37 HRAS KRAS PIK3CA TP53
48
Show member pathways
12.37 BRAF FGFR1 FGFR2 HRAS KRAS PIK3CA
49 12.35 BRAF EGFR FGFR1 HRAS KRAS PIK3CA
50
Show member pathways
12.35 EGFR FGFR1 FGFR2 HRAS KRAS PIK3CA

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.96 ALK BRAF EGFR FGFR1
2 protein phosphorylation GO:0006468 9.95 ALK BRAF EGFR FGFR1 FGFR2 PIK3CA
3 regulation of gene expression GO:0010468 9.94 FGFR1 PIK3CA PTHLH SOX2
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 BRAF EGFR FGFR2 HRAS
5 protein autophosphorylation GO:0046777 9.91 ALK EGFR FGFR1 FGFR2
6 peptidyl-tyrosine phosphorylation GO:0018108 9.89 ALK EGFR FGFR1 FGFR2
7 positive regulation of protein kinase B signaling GO:0051897 9.88 EGFR FGFR1 FGFR2 PIK3CA
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 BRAF EGFR PIK3CA
9 Ras protein signal transduction GO:0007265 9.82 HRAS KRAS TP53
10 phosphatidylinositol phosphorylation GO:0046854 9.81 EGFR FGFR1 FGFR2 PIK3CA
11 positive regulation of epithelial cell proliferation GO:0050679 9.79 EGFR FGFR2 HRAS
12 positive regulation of MAPK cascade GO:0043410 9.78 FGFR1 FGFR2 HRAS SOX2
13 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.76 FGFR1 FGFR2 PIK3CA
14 liver development GO:0001889 9.73 CYP1A1 EGFR KRAS PIK3CA
15 positive regulation of cell cycle GO:0045787 9.72 FGFR1 FGFR2 TP53
16 cellular response to drug GO:0035690 9.67 BRAF EGFR NFE2L2 TP53
17 branching involved in salivary gland morphogenesis GO:0060445 9.66 FGFR1 FGFR2
18 salivary gland morphogenesis GO:0007435 9.65 EGFR FGFR1
19 mesenchymal cell differentiation GO:0048762 9.65 FGFR1 FGFR2
20 response to isolation stress GO:0035900 9.64 HRAS KRAS
21 positive regulation of phospholipase activity GO:0010518 9.63 FGFR1 FGFR2
22 lung-associated mesenchyme development GO:0060484 9.63 FGFR1 FGFR2
23 positive regulation of MAP kinase activity GO:0043406 9.62 EGFR FGFR1 HRAS KRAS
24 proteasomal ubiquitin-independent protein catabolic process GO:0010499 9.57 KEAP1 NFE2L2
25 orbitofrontal cortex development GO:0021769 9.56 FGFR1 FGFR2
26 epidermal growth factor receptor signaling pathway GO:0007173 9.56 EGFR HRAS KRAS PIK3CA
27 negative regulation of neuron apoptotic process GO:0043524 9.55 BRAF HRAS KRAS PIK3CA PRKCI
28 ventricular zone neuroblast division GO:0021847 9.52 FGFR1 FGFR2
29 fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development GO:0035607 9.49 FGFR1 FGFR2
30 MAPK cascade GO:0000165 9.43 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
31 ERBB2 signaling pathway GO:0038128 8.92 EGFR HRAS KRAS PIK3CA
32 positive regulation of gene expression GO:0010628 10.01 BRAF HRAS KRAS NFE2L2 TP53
33 positive regulation of cell proliferation GO:0008284 10.01 EGFR FGFR1 FGFR2 HRAS KRAS PTHLH
34 cell proliferation GO:0008283 10 ALK CYP1A1 EGFR HRAS TP53
35 phosphorylation GO:0016310 10 ALK BRAF EGFR FGFR1 FGFR2 PIK3CA

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.8 ALK BRAF EGFR FGFR1 FGFR2 PRKCI
2 kinase activity GO:0016301 9.8 ALK BRAF EGFR FGFR1 FGFR2 PIK3CA
3 protein tyrosine kinase activity GO:0004713 9.73 ALK EGFR FGFR1 FGFR2
4 1-phosphatidylinositol-3-kinase activity GO:0016303 9.54 FGFR1 FGFR2 PIK3CA
5 transcription cofactor binding GO:0001221 9.48 NFE2L2 TP53
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 EGFR FGFR1 FGFR2 PIK3CA
7 fibroblast growth factor-activated receptor activity GO:0005007 9.4 FGFR1 FGFR2
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.26 ALK EGFR FGFR1 FGFR2
9 nucleotide binding GO:0000166 9.17 BRAF EGFR FGFR1 FGFR2 HRAS KRAS
10 ATP binding GO:0005524 10.06 ALK BRAF EGFR FGFR1 FGFR2 PIK3CA

Sources for Lung Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....